Mirna Chehade, MD, MPH; Director

Clinic Office Hours:

Tuesday: 9:00am-12:00pm

Wednesday: 9:00am-12:00pm

Thursday: 9:00am-12:00pm

Contact Information:

Telephone: 212-241-4880

Biography

Dr. Mirna Chehade, MD, MPH is Professor of Pediatrics and Medicine at the Icahn School of Medicine at Mount Sinai in New York, NY. She is a is a nationally and internationally recognized expert in eosinophilic gastrointestinal disorders (EGIDs), including eosinophilic esophagitis (EoE). She is a Professor of Pediatrics and Medicine at the Icahn School of Medicine at Mount Sinai and is the founding director of the Mount Sinai Center for Eosinophilic Disorders (MSCED), one of the few centers in the world dedicated to comprehensive, multidisciplinary EGID care for both children and adults.

At the MSCED, Dr. Chehade diagnoses and treats children and adults with EGIDs and provides cutting-edge research, and personalized medical care to patients and their families. Her holistic approach ensures that each patient receives not only medical treatment but also nutritional, feeding, and psychological support, acknowledging the complexity of EGIDs beyond their physical symptoms and the impact on their families as well. Under her leadership, MSCED has become a leading national and international referral center, offering innovative treatment strategies, multidisciplinary care, and access to clinical trials.

Dr. Chehade’s clinical excellence has been recognized with numerous accolades, including:

Yearly recognition as a Castle Connolly Top Doctor in Pediatric Gastroenterology since 2013
Cullman Family Award for Excellence in Physician Communication (2020)
Fellow of the American Gastroenterological Association (AGA) and the American Academy of Allergy, Asthma, and Immunology (AAAAI) (2021)

Dr. Chehade is also at the forefront of research and clinical advancements in EGIDs, with her work directly influencing treatment protocols, guidelines, and therapeutic development. She has authored or co-authored over 92 peer-reviewed original research papers, 29 review articles, 13 book chapters, and 7 invited editorials, shaping the evolving landscape of EGID treatment. She is a site Principal Investigator (PI) in multiple NIH-funded studies such as CEGIR, including the NIH U54 CEGIR Consortium and has led multi-center trials that resulted in landmark publications in The New England Journal of Medicine.

Her groundbreaking research has significantly advanced the diagnosis, treatment, and long-term management of EGIDs, including:

Establishing long-term safety and efficacy guidelines for topical corticosteroids in EoE
Identifying reasons for why there are delays in diagnosing in patients with Eosinophilic Gastritis
Leading multi-center studies on dietary and pharmacologic therapies for EGIDs
Examining long term outcomes of patients with EGIDs
Playing a critical role in the development of the first and only FDA-approved therapy for pediatric EoE ([Chehade M et al, N Engl J Med 2024]).

She serves as Chair of the Rare Diseases Clinical Research Network Diversity Sub-Committee, Associate Chair of the CEGIR Diversity Research Sub-Committee, and is an active member of AAAAI, EAACI, NASPGHAN, and AGA. Additionally, she volunteers as a Medical Advisory Board member for the American Partnership for Eosinophilic Disorders (APFED) and the Campaign Urging Research for Eosinophilic Disease (CURED). She has also served as an expert on FDA panels to help advance and shape the field. Dr. Chehade is also frequently invited speaker at national and international meetings, and an invited reviewer for a number of highly ranked gastroenterology and allergy journals.

In addition to all of her accolades Dr. Chehade is a dedicated mentor and educator, training the next generation of physicians, researchers, and scholars in EGIDs. Her mentorship spans from high school students, medical students, residents and fellows to international scholars, physicians and faculty. Several of her trainees have been awarded grants, presented posters, oral abstracts and published journal articles.